An update on cardiovascular adrenergic receptor physiology and potential pharmacological applications in veterinary critical care

Journal of Veterinary Emergency and Critical Care

Volumn 18, Issue 1, 2008, Pages 2-25

  Long, Kathryn M ^a,b   Kirby, Rebecca ^a  

^a Animal Emergency Center   (United States)

^b NONE   (United States)

Author keywords

receptor; receptor; Adrenergic receptor agonist; Adrenergic receptor antagonist; Catecholamine

Indexed keywords

ANIMALIA;

EID: 38849098360     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2007.00266.x     Document Type: Review

References (191)

1. Tsuru H, Tanimitsu N, Hirai T. Role of perivascular sympathetic nerves and regional differences in the features of sympathetic innervation of the vascular system. Jpn J Pharmacol 2002 88 : 9 13.
2. Lu CL, Tung CS, Jordan J, et al. Autonomic cardiovascular control: lessons from autonomic disorders. J Med Sci 2003 23 : 243 248.
3. Goldstein DS, Robertson D, Esler M, et al. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 2002 137 : 753 763.
4. Julien C, Malpas SC, Stauss HM. Sympathetic modulation of blood pressure variability. J Hypertens 2001 19 : 1707 1712.
5. Brook RD, Julius S. Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens 2000 13 : 112S 122S.
6. Chiba S, Yang XP. Neuroeffector mechanisms involved in the regulation of dog splenic arterial tone. J Pharmacol Sci 2003 92 : 84 92.
7. Asamoto K. Network of the sympathetic nervous system: focus on the input and output of the cervical sympathetic ganglion. Anat Sci Int 2005 80 : 132 140.
8. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001 53 : 319 356.
9. Pang CC. Autonomic control of the venous system in health and disease: effects of drugs. Pharmacol Ther 2001 90 : 179 230.
10. Bennett MR, Cheung A, Brain KL. Sympathetic neuromuscular transmission at a varicosity in a syncytium. Microsc Res Tech 1998 42 : 433 450.
11. Vincent S, Robertson D. The broader view: catecholamine abnormalities. Clin Auton Res 2002 12 (Suppl. 1) : I44 I49.
12. Kuroko Y, Fujii T, Yamazaki T, et al. Contribution of catechol O-methyltransferase to the removal of accumulated interstitial catecholamines evoked by myocardial ischemia. Neurosci Lett 2005 388 : 61 64.
13. 2-adrenoceptor subtypes. Mol Endocrinol 2003 17 : 1640 1646.
14. Klein RL, Yabuno N, Peeler DF, et al. Adrenal enkephalin and catecholamine contents following subarachnoid hemorrhage in cats. Neuropeptides 1986 8 : 143 158.
15. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004 56 : 331 349.
16. McCarty R, Pacak K, Goldstein DS, et al. Regulation of peripheral catecholamine responses to acute stress in young adult and aged F-344 rats. Stress 1997 2 : 113 122.
17. Ruffolo RRJ. Distribution and function of peripheral alpha-adrenoceptors in the cardiovascular system. Pharmacol Biochem Behav 1985 22 : 827 833.
18. Riemann B, Schafers M, Law MP, et al. Radioligands for imaging myocardial alpha- and beta-adrenoceptors. Nuklearmedizin 2003 42 : 4 9.
19. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 2001 104 : 2194 2199.
20. Molenaar P, Parsonage WA. Fundamental considerations of beta-adrenoceptor subtypes in human heart failure. Trends Pharmacol Sci 2005 26 : 368 375.
21. El-Armouche A, Zolk O, Rau T, et al. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 2003 60 : 478 487.
22. Ahlquist RF. A study of the adrenotropic receptors. Am J Physiol 1948 153 : 586 600.
23. 1-adrenoceptor subtypes: functions and signaling. Can J Physiol Pharmacol 2000 78 : 267 292.
24. 1- adrenoceptors: consensus update. Pharmacol Rev 1995 47 : 267 270.
25. Opie LH. Receptors and signal transduction, In : Opie LH. ed. Heart Physiology: From Cell to Circulation. Philadelphia : Lippincott Williams & Wilkins 2004, pp. 186 220.
26. Raymond JR, Hnatowich M, Lefkowitz RJ, et al. Adrenergic receptors. Models for regulation of signal transduction processes. Hypertension 1990 15 : 119 131.
27. 1-adrenoceptors. Curr Med Chem 2001 8 : 607 620.
28. 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci USA 1990 87 : 2896 2900.
29. 2-adrenoceptor-mediated functional responses. J Auton Pharmacol 1999 19 : 335 345.
30. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004 125 : 2309 2321.
31. Hieble JP. Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. Pharm Acta Helv 2000 74 : 163 171.
32. 1-adrenoceptor pharmacology. Biol Pharm Bull 2002 25 : 401 408.
33. Zheng M, Zhu W, Han Q, et al. Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. Pharmacol Ther 2005 108 : 257 268.
34. Dzimiri N. Regulation of beta-adrenoceptor signaling in cardiac function and disease. Pharmacol Rev 1999 51 : 465 501.
35. 1-adrenoceptors: subtypes, signaling, and roles in health and disease. Arch Med Res 1999 30 : 449 458.
36. 1 adrenoceptor function in health and disease from transgenic animal studies. Trends Endocrinol Metab 2003 14 : 107 113.
37. 1-adrenoceptor pharmacology. Pharmacol Ther 2003 98 : 235 244.
38. Willems EW, Valdivia LF, Villalon CM, et al. Possible role of alpha-adrenoceptor subtypes in acute migraine therapy. Cephalalgia 2003 23 : 245 257.
39. 2C-adrenoceptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2001 364 : 117 130.
40. 1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 1999 359 : 439 446.
41. 1-adrenoceptor subtypes in aortas of 12-month-old spontaneously hypertensive rats. Eur J Pharmacol 1998 344 : 31 36.
42. 2 adrenergic receptor subtypes. Life Sci 1998 62 : 1467 1472.
43. 2-adrenergic receptor subtypes. J Biol Chem 1994 269 : 10093 10099.
44. Corti R, Burnett JCJ, Rouleau JL, et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001 104 : 1856 1862.
45. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001 38 : 581 587.
46. 2 adrenoceptor-mediated pressor responses in pithed rats. J Pharmacol Exp Ther 1980 214 : 275 281.
47. Bevan JA, Duckworth J, Laher I, et al. Sympathetic control of cerebral arteries: specialization in receptor type, reserve, affinity, and distribution. FASEB J 1987 1 : 193 198.
48. 1 adrenoceptors: evaluation of receptor subtype-binding kinetics in intact arterial tissues and comparison with membrane binding. Br J Pharmacol 2004 141 : 468 476.
49. Kwan DC. Heterogeneity of vascular smooth muscle alpha-adrenoceptors in canine blood vessels. Clin Exp Pharmacol Physiol 1999 26 : 822 823.
50. 1D- adrenoceptor subtypes. J Pharmacol Exp Ther 2003 305 : 1045 1053.
51. 1D-adrenoceptors: are they related to hypertension? Arch Med Res 1999 30 : 347 352.
52. 1-adrenoceptor subtypes. Circ Res 2001 89 : 815 822.
53. 2-adrenoceptors. Eur J Pharmacol 1998 361 : 1 15.
54. Leech CJ, Faber JE. Different alpha-adrenoceptor subtypes mediate constriction of arterioles and venules. Am J Physiol 1996 270 : H710 H722.
55. Langer SZ, Shepperson NB, Massingham R. Preferential noradrenergic innervation of alpha-adrenergic receptors in vascular smooth muscle. Hypertension 1981 3 : I112 I118.
56. 2-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004 286 : H59 H67.
57. 2-adrenoceptor polymorphisms in cardiovascular diseases. Int J Cardiol 2004 97 : 367 372.
58. 2C-adrenoceptor translocation. Circ Res 2004 94 : 1367 1374.
59. 2 adrenergic responses in canine saphenous and femoral veins. J Pharmacol Exp Ther 1986 238 : 139 147.
60. Roberts M, Rivers T, Oliveria S, et al. Adrenoceptor and local modulator control of cutaneous blood flow in thermal stress. Comp Biochem Physiol A Mol Integr Physiol 2002 131 : 485 496.
61. 2 adrenoceptors: differential distribution in arteries of the limbs. J Pharmacol Exp Ther 1987 241 : 361 365.
62. Langer SZ. 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol Sci 1997 18 : 95 99.
63. Lowenthal DT, Saris SD, Haratz A, et al. The clinical pharmacology of antihypertensive drugs. J Hypertens 1984 2 (Suppl.) : S13 S24.
64. 1 adrenergic responses in canine saphenous veins. J Pharmacol Exp Ther 1987 240 : 589 593.
65. Flavahan NA, Vanhoutte PM. Sympathetic purinergic vasoconstriction and thermosensitivity in a canine cutaneous vein. J Pharmacol Exp Ther 1986 239 : 784 789.
66. 1-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1987 335 : 397 402.
67. 2- adrenoceptor activation increases from the distal to the proximal part of the veins of canine limbs. Br J Pharmacol 1990 101 : 387 393.
68. 2-adrenoceptors of the dog mesenteric and rat femoral veins. Naunyn Schmiedebergs Arch Pharmacol 1999 360 : 165 170.
69. 1-adrenoceptor subtypes in porcine coronary artery. Clin Exp Pharmacol Physiol 1998 25 : 682 685.
70. Heusch G, Baumgart D, Camici P, et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000 101 : 689 694.
71. Tune JD, Gorman MW, Feigl EO. Matching coronary blood flow to myocardial oxygen consumption. J Appl Physiol 2004 97 : 404 415.
72. Begonha R, Moura D, Guimaraes S. Vascular beta-adrenoceptor-mediated relaxation and the tone of the tissue in canine arteries. J Pharm Pharmacol 1995 47 : 510 513.
73. 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med 1989 87 : 1S 5S.
74. Richard V, Tanner FC, Tschudi M, et al. Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol 1990 259 : H1433 H1439.
75. 2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. J Pharmacol Exp Ther 1996 278 : 1235 1243.
76. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983 305 : 627 630.
77. 2-adrenoceptors is necessary to induce nitric oxide release in isoprenaline-induced relaxation. Vascul Pharmacol 2005 42 : 63 68.
78. McMillon RK, Townsley MI. Alpha-adrenergic vasoreactivity of canine intrapulmonary bronchial arteries in pacing-induced heart failure. Am J Physiol 1999 277 : H1392 H1402.
79. Miller VM, Vanhoutte PM. Endothelium-dependent responses and their potential relevance to the distribution of blood flow during hemorrhagic shock. Resuscitation 1989 18 : 165 171.
80. 1-adrenoceptor: inotropic effect and physiologic and pathologic implications. Life Sci 1997 60 : 1305 1318.
81. Brodde OE, Bruck H, Leineweber K, et al. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 2001 96 : 528 538.
82. Brodde OE, Leineweber K. Autonomic receptor systems in the failing and aging human heart: similarities and differences. Eur J Pharmacol 2004 500 : 167 176.
83. Schluter KD, Piper HM. Regulation of growth in the adult cardiomyocytes. FASEB J 1999 13 (Suppl.) : S17 S22.
84. 1B-adrenergic receptor induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2001 281 : H931 H998.
85. 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart. J Biol Chem 2004 279 : 54053 54061.
86. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 2002 40 : 323 338.
87. Li K, Rouleau JL. Tension-frequency relationships in normal and cardiomyopathic dog and hamster myocardium. J Mol Cell Cardiol 1995 27 : 1251 1261.
88. 1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 1997 280 : 721 729.
89. 1-receptor subtypes. J Cardiovasc Electrophysiol 1997 8 : 658 666.
90. 1A-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 2001 364 : 444 453.
91. 1-adrenoceptor subtypes in mediating cardiomyocyte protein synthesis in neonatal rats. Clin Exp Pharmacol Physiol 2004 31 : 626 633.
92. 1-adrenergic receptor subtype mRNAs. J Mol Cell Cardiol 1998 30 : 1515 1523.
93. Li K, Rouleau JL, Calderone A, et al. Endocardial function in pacing-induced heart failure in the dog. J Mol Cell Cardiol 1993 25 : 529 540.
94. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984 311 : 819 823.
95. Lands AM, Arnold A, McAuliff JP, et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967 214 : 597 598.
96. Collins S, Cao W, Robidoux J. Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol Endocrinol 2004 18 : 2123 2131.
97. Tanaka Y, Horinouchi T, Koike K. New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. Clin Exp Pharmacol Physiol 2005 32 : 503 514.
98. 3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 2000 21 : 426 431.
99. Xiao RP, Zhu W, Zheng M, et al. Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 2004 25 : 358 365.
100. Kaumann AJ, Molenaar P. Modulation of human cardiac function through 4 beta-adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol 1997 355 : 667 681.
101. Boudreau G, Peronnet F, De Champlain J, et al. Presynaptic effects of epinephrine on norepinephrine release from cardiac sympathetic nerves in dogs. Am J Physiol 1993 265 : H205 H211.
102. Yamaguchi N, de Champlain J, Nadeau RA. Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors. Circ Res 1977 41 : 108 117.
103. de Jong RM, Blanksma PK, van Waarde A, et al. Measurement of myocardial beta-adrenoceptor density in clinical studies: a role for positron emission tomography? Eur J Nucl Med Mol Imaging 2002 29 : 88 97.
104. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993 22 : 61A 71A.
105. 2-adrenergic receptor. Proc Natl Acad Sci USA 1993 90 : 3665 3669.
106. 2-adrenergic receptors. J Biol Chem 1999 274 : 16701 16708.
107. 2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997 390 : 88 91.
108. 2+/calmodulin kinase signaling pathway. Circ Res 2004 95 : 798 806.
109. 2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res 2000 87 : 1172 1179.
110. Ahmet I, Krawczyk M, Heller P, et al. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 2004 110 : 1083 1090.
111. Massion PB, Moniotte S, Balligand JL. Nitric oxide: does it play a role in the heart of the critically ill? Curr Opin Crit Care 2001 7 : 323 336.
112. 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 1996 278 : 1435 1443.
113. Rapps JA, Sturek M, Jones AW, et al. Altered reactivity of coronary arteries located distal to a chronic coronary occlusion. Am J Physiol 1997 273 : H1879 H1887.
114. Alonso MJ, Salaices M, Sanchez-Ferrer CF, et al. Nitric-oxide-related and non-related mechanisms in the acetylcholine-evoked relaxations in cat femoral arteries. J Vasc Res 1993 30 : 339 347.
115. Yang BC, Nicolini FA, Nichols WW, et al. Decreased endothelium-dependent vascular relaxation following subtotal coronary artery occlusion in dogs. Free Radic Biol Med 1993 14 : 295 302.
116. Parent R, al-Obaidi M, Lavallee M. Nitric oxide formation contributes to beta-adrenergic dilation of resistance coronary vessels in conscious dogs. Circ Res 1993 73 : 241 251.
117. 3- adrenoceptors among other beta-adrenoceptor subtypes in the regulation of the cardiovascular system. Arch Mal Coeur Vaiss 2003 96 : 905 913.
118. Cohn JN. Left ventricle and arteries: structure, function, hormones and disease. Hypertension 2001 37 (Part 2) : 346 349.
119. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother 2004 38 : 649 660.
120. Hermann HP. Energetic stimulation of the heart. Cardiovasc Drugs Ther 2001 15 : 405 411.
121. Levine BS. Intermittent positive inotrope infusion in the management of end-stage, low-output heart failure. J Cardiovasc Nurs 2000 14 : 76 93.
122. Capomolla S, Febo O, Opasich C, et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 2001 3 : 601 610.
123. Scrutinio D, Napoli V, Passantino A, et al. Low-dose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome. Eur Heart J 2000 21 : 927 934.
124. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999 138 : 247 253.
125. Albert NM, Eastwood CA, Edwards ML. Evidence-based practice for acute decompensated heart failure. Crit Care Nurse 2004 24 : 14 16 quiz 30-1.
126. Lowery SL, Massaro R, Yancy CWJ. Advances in the management of acute and chronic decompensated heart failure. Lippincotts Case Manag 2004 9 : S1 S15 quiz S16-S17.
127. Emerman CL. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department. Rev Cardiovasc Med 2003 4 (Suppl. 7) : S13 S20.
128. Lowes BD, Simon MA, Tsvetkova TO, et al. Inotropes in the beta-blocker era. Clin Cardiol 2000 23 : III11 III16.
129. Abbott JA. Beta-blockade in the management of systolic dysfunction. Vet Clin North Am Small Anim Pract 2004 34 : 1157 1170.
130. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000 101 : 558 569.
131. Ruffolo RRJ, Feuerstein GZ, Ohlstein EH. Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure. Am J Hypertens 1998 11 : 9S 14S.
132. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003 100 : 215 234.
133. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996 94 : 2285 2296.
134. 1- adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int Urol Nephrol 2001 33 : 407 412.
135. Zhu J, Wang D, Lu Z, et al. Hemodynamic effects of terazosin in congestive heart failure. Chin Med Sci J 1993 8 : 98 100.
136. 1-adrenergic blocking agents. J Clin Pharmacol 1993 33 : 2 13.
137. 1-adrenergic blocking drugs. Drug Saf 1994 11 : 12 20.
138. 1 adrenergic blockade and angiotensin converting enzyme inhibition in the treatment of congestive heart failure. Int J Cardiol 1996 57 : 173 176.
139. Kukin ML, Kalman J, Mannino M, et al. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Am J Cardiol 1996 77 : 486 491.
140. Lang CC, Choy AM, Rahman AR, et al. Renal effects of low dose prazosin in patients with congestive heart failure. Eur Heart J 1993 14 : 1245 1252.
141. Abbott JA, Broadstone RV, Ward DL, et al. Hemodynamic effects of orally administered carvedilol in healthy conscious dogs. Am J Vet Res 2005 66 : 637 641.
142. Uechi M, Sasaki T, Ueno K, et al. Cardiovascular and renal effects of carvedilol in dogs with heart failure. J Vet Med Sci 2002 64 : 469 475.
143. 1-adrenergic blockade and sudden cardiac death. J Cardiovasc Electrophysiol 1994 5 : 76 89.
144. 2-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens 2001 19 : 2115 2124.
145. 2-adrenoceptors in congestive heart failure. Am Heart J 1995 130 : 516 521.
146. Broadley KJ, Penson PE. The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia. Auton Autacoid Pharmacol 2004 24 : 87 93.
147. 1-adrenoreceptors? Chest 2001 119 : 1242 1249.
148. 1-adrenoceptor binding characteristics of the guinea-pig perfused heart during ischaemia and reperfusion. J Mol Cell Cardiol 1990 22 : 599 606.
149. 1-adrenergic receptor antagonists on susceptibility to malignant arrhythmias: protection from ventricular fibrillation. J Cardiovasc Pharmacol 1994 24 : 394 402.
150. 1D-adrenoceptor: molecular and cellular characteristics and integrative roles. Eur J Pharmacol 2004 500 : 113 120.
151. Chetboul V, Lefebvre HP, Pinhas C, et al. Spontaneous feline hypertension: clinical and echocardiographic abnormalities, and survival rate. J Vet Intern Med 2003 17 : 89 95.
152. Littman MP. Spontaneous systemic hypertension in 24 cats. J Vet Intern Med 1994 8 : 79 86.
153. Jacob F, Polzin DJ, Osborne CA, et al. Association between initial systolic blood pressure and risk of developing a uremic crisis or of dying in dogs with chronic renal failure. J Am Vet Med Assoc 2003 222 : 322 329.
154. Michell AR. Salt, hypertension and renal disease: comparative medicine, models and real diseases. Postgrad Med J 1994 70 : 686 694.
155. Floras JS. Epinephrine and the genesis of hypertension. Hypertension 1992 19 : 1 18.
156. 2-adrenoceptors in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 1990 16 : 354 359.
157. Rumantir MS, Jennings GL, Lambert GW, et al. The 'adrenaline hypothesis' of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension. J Hypertens 2000 18 : 717 723.
158. Leenen FH. Cardiovascular consequences of sympathetic hyperactivity. Can J Cardiol 1999 15 (Suppl. A) : 2A 7A.
159. Dupont AG. Carvedilol and the kidney. Clin Investig 1992 70 (Suppl. 1) : S127 S131.
160. 1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens 1996 9 : 139S 149S.
161. 1-adrenergic receptor research. Acta Pharmacol Sin 2005 26 : 1281 1287.
162. 1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol 2005 67 : 912 922.
163. 2-adrenergic receptor subtypes b and c. Science 1996 273 : 803 805.
164. 2-adrenergic receptors in hypertension. Am J Hypertens 2001 14 : 171S 177S.
165. 2B-adrenergic receptors in blood pressure control and hypertension. J Hypertens 2003 21 : 871 872.
166. 2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension 1999 33 : 14 17.
167. Widdicombe JG. Neural control of airway vasculature and edema. Am Rev Respir Dis 1991 143 : S18 S21.
168. Oriowo MA. Different atypical beta-adrenoceptors mediate isoprenaline-induced relaxation in vascular and non-vascular smooth muscles. Life Sci 1995 56 : PL269 PL275.
169. Tamaoki J, Tagaya E, Isono K, et al. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cAMP-dependent pathway. Biochem Biophys Res Commun 1998 248 : 722 727.
170. 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 1999 128 : 69 76.
171. Hinder F, Stubbe HD, Van Aken H, et al. Early multiple organ failure after recurrent endotoxemia in the presence of vasoconstrictor-masked hypovolemia. Crit Care Med 2003 31 : 903 909.
172. Treggiari MM, Romand JA, Burgener D, et al. Effect of increasing norepinephrine dosage on regional blood flow in a porcine model of endotoxin shock. Crit Care Med 2002 30 : 1334 1339.
173. Kellum JA, Pinsky MR. Use of vasopressor agents in critically ill patients. Curr Opin Crit Care 2002 8 : 236 241.
174. Vincent JL, De Backer D. Inotrope/vasopressor support in sepsis-induced organ hypoperfusion. Semin Respir Crit Care Med 2001 22 : 61 74.
175. Beale RJ, Hollenberg SM, Vincent JL, et al. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 2004 32 : S455 S465.
176. Mullner M, Urbanek B, Havel C, et al. Vasopressors for shock. Cochrane Database Syst Rev 2004 CD003709.
177. Pearson JW, Redding JS. Peripheral vascular tone on cardiac resuscitation. Anesth Analg 1965 44 : 746 752.
178. Redding JS, Pearson JW. Evaluation of drugs for cardiac resuscitation. Anesthesiology 1963 24 : 203 207.
179. Redding JS, Pearson JW. Resuscitation from ventricular fibrillation. Drug therapy. JAMA 1968 203 : 255 260.
180. Roberts D, Landolfo K, Dobson K, et al. The effects of methoxamine and epinephrine on survival and regional distribution of cardiac output in dogs with prolonged ventricular fibrillation. Chest 1990 98 : 999 1005.
181. Tang W, Weil MH, Sun S, et al. Epinephrine increases the severity of postresuscitation myocardial dysfunction. Circulation 1995 92 : 3089 3093.
182. Thrush DN, Downs JB, Smith RA. Is epinephrine contraindicated during cardiopulmonary resuscitation? Circulation 1997 96 : 2709 2714.
183. Martin GB, Gentile NT, Paradis NA, et al. Effect of epinephrine on end-tidal carbon dioxide monitoring during CPR. Ann Emerg Med 1990 19 : 396 398.
184. Cao L, Weil MH, Sun S, et al. Vasopressor agents for cardiopulmonary resuscitation. J Cardiovasc Pharmacol Ther 2003 8 : 115 121.
185. Huang L, Weil MH, Cammarata G, et al. Nonselective beta-blocking agent improves the outcome of cardiopulmonary resuscitation in a rat model. Crit Care Med 2004 32 : S378 S380.
186. Huang L, Weil MH, Sun S, et al. Carvedilol mitigates adverse effects of epinephrine during cardiopulmonary resuscitation. J Cardiovasc Pharmacol Ther 2005 10 : 113 120.
187. Klouche K, Weil MH, Sun S, et al. A comparison of alpha- methylnorepinephrine, vasopressin and epinephrine for cardiac resuscitation. Resuscitation 2003 57 : 93 100.
188. Guyette FX, Guimond GE, Hostler D, et al. Vasopressin administered with epinephrine is associated with a return of a pulse in out-of-hospital cardiac arrest. Resuscitation 2004 63 : 277 282.
189. Weil MH, Tang W. Cardiopulmonary resuscitation: a promise as yet largely unfulfilled. Dis Mon 1997 43 : 429 501.
190. 2-selective vasopressor agent for cardiopulmonary resuscitation. Circulation 2003 108 : 2716 2721.
191. 2-adrenergic agonist for cardiac resuscitation. J Am Coll Cardiol 2001 37 : 951 956.